Merz North America, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$31.2M
Doctors Paid
22,512
Transactions
119,764
2024 Total
$3.4M
Payment Breakdown by Category
Research$9.7M (31.1%)
Consulting$8.2M (26.1%)
Food & Beverage$7.7M (24.5%)
Travel$3.2M (10.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.7M | 1,485 | 31.1% |
| Consulting Fee | $8.2M | 2,347 | 26.1% |
| Food and Beverage | $7.7M | 109,662 | 24.5% |
| Travel and Lodging | $3.2M | 4,715 | 10.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $908,271 | 218 | 2.9% |
| Honoraria | $815,233 | 248 | 2.6% |
| Charitable Contribution | $406,250 | 31 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $128,095 | 68 | 0.4% |
| Grant | $125,000 | 12 | 0.4% |
| Education | $44,844 | 884 | 0.1% |
| Gift | $36,350 | 90 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $22,995 | 4 | 0.1% |
Payments by Type
General
$21.5M
118,279 transactions
Research
$9.7M
1,485 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Prospective, Multicenter, Controlled, Evaluator-blind, Randomized Study to Investigate the Effectiveness and Safety of Diluted RADIESSE for Treatment of Decollete Wrinkles | $1.5M | 7 | 91 |
| Evaluation of Effectiveness and Safety of Belotero Balance Lidocaine for Volume Augmentation of the Infraorbital Hollow | $1.2M | 3 | 63 |
| EVALUATION OF EFFECTIVENESS AND SAFETY OF RADIESSE (+) TO IMPROVE THE CONTOUR OF JAWLINE BY ADDING VOLUME TO THE JAWLINE | $850,373 | 0 | 182 |
| STUDY TO INVESTIGATE THE SAFETY AND DURATION OF EFFECT OF DIFFERENT BOTULINUM TOXIN A (NT 201) DOSE GROUPS FOLLOWING THE TREATMENT OF GLABELLAR FROWN LINES | $743,474 | 2 | 102 |
| EVALUATION OF THE SENSITIVITY OF THE MERZ INFRAORBITAL HOLLOW SCALE AND SAFETY OF BELOTERO BALANCE INJECTION FOR VOLUME AUGMENTATION OF THE INFRAORBITAL HOLLOW | $650,013 | 1 | 35 |
| RADIESSE POST APPROVAL STUDY (PAS) FOR TREATMENT OF HANDS WITH MODERATE TO VERY SEVERE DORSAL VOLUME LOSS | $617,400 | 1 | 65 |
| Evaluation of the Octave Platform for the Ulthera System for Improving Laxity and Wrinkles on the Decollete | $529,760 | 5 | 69 |
| M900391004 - RADIESSE JAWLINE PIVOTAL STUDY | $326,444 | 0 | 104 |
| PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NT 201 IN THE TREATMENT OF LOWER LIMB SPASTICITY CAUSED BY STROKE OR TRAUMATIC BRAIN INJURY IN ADULT SUBJECTS, FOLLOWED BY AN OPEN LABEL EXTENSION WITH OR WITHOUT COMBINED UPPER LIMB TREATMENT | $306,658 | 19 | 295 |
| M930121002 - BELOTERO BALANCE INFRAORBITAL HOLLOW (IOH) PIVOTAL STUDY. | $291,720 | 0 | 32 |
| EVALUATION OF EFFECTIVENESS AND SAFETY OF RADIESSE (+) FOR THE IMPROVEMENT OF JAWLINE VOLUME AND CONTOUR | $274,772 | 19 | 172 |
| A prospective, randomized, double-blind, placebo-controlled, single-center exploratory study to investigate NT 201 in the treatment of enlarged pores and excessive sebum production in the face | $262,834 | 0 | 13 |
| Prospective, evaluator-blind, multicenter study to assess the safety and effectiveness of treatment with the Octave System for lifting the eyebrow and improving the appearance of the face and neck | $211,290 | 5 | 26 |
| OPEN-LABEL PROSPECTIVE EVALUATION OF THE ULTHERA SYSTEM FOR LIFTING SUBMENTAL (UNDER THE CHIN) A\ND NECK TISSUE IN CHINESE SUBJECTS. | $185,075 | 0 | 22 |
| M930121001 - BELOTERO BALANCE INFRAORBITAL HOLLOW (IOH) PILOT STUDY. | $181,926 | 0 | 14 |
| M960001057 - ULTHERAPY DEEPSEE SUBMENTUM OBSERVATIONAL STUDY | $180,851 | 0 | 11 |
| A PROSPECTIVE, RANDOMIZED, SINGLE CENTER, EVALUATOR BLINDED CLINICAL TRIAL EVALUATING THE SAFETY, EFFICACY, AND PATIENT SATISFACTION OF INJECTABLE CALCIUM HYDROXYLAPATITE (RADIESSE PLUS, MERZ AESTHETICS) IN COMBINATION WITH MICRO FOCUSED ULTRASOUND FOR REJUVENATION OF THE AGING CHEST | $125,550 | 0 | 2 |
| EVALUATION OF PAIN WITH BELOTERO BALANCE WITH INTEGRAL LIDOCAINE FOR CORRECTION OF THE NASOLABIAL FOLDS | $116,461 | 0 | 9 |
| A PROSPECTIVE, RANDOMIZED, SINGLE-CENTER, OPEN-LABEL CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF MICROFOCUSED ULTRASOUND USING STANDARD TREATMENT LINE PROTOCOL VERSUS TARGETED TISSUE PROTOCOL FOR LIFTING AND TIGHTENING OF THE LOWER FACE AND NECK | $108,201 | 0 | 4 |
| AN OPEN-LABEL 2 ARMED TRIAL TO ASSESS THE EFFICACY OF 3 STACKED TREAMENTS UTILIZING MORE PRECISE CUSTOMIZED ANATOMICAL CONSIDERATIONS COMPARED TO A SINGLE TREATMENT | $97,500 | 0 | 3 |
| A PILOT STUDY EXAMINING THE EFFICIENCY OF PREMIXED CALCIUM HYDROXYLAPATITE FILLER WITH LIDOCAINE TO CORRECT JAWLINE AND CHIN VOLUME LOSS | $77,250 | 0 | 1 |
| SAFETY AND EFFICACY STUDY OF THE SIMULTANEOUS TREATMENT OF UPPER FACIAL LINES (HORIZONTAL FOREHEAD LINES, GLABELLAR FROWN LINES AND LATERAL CANTHAL LINES) IN SUBJECTS WITH MODERATE TO SEVERE UPPER FACIAL LINES (ULTRA I) | $69,932 | 0 | 9 |
| PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, DOSE RESPONSE STUDY OF THREE DOSES XEOMIN (INCOBOTULINUMTOXINA, NT 201) FOR THE TREATMENT OF UPPER LIMB SPASTICITY ALONE OR COMBINED UPPER AND LOWER LIMB SPASTICITY IN CHILDREN AND ADOLESCENTS (AGE 2 17 YEARS) WITH CEREBRAL PALSY | $58,237 | 0 | 36 |
| A BILATERAL PAIRED SUBJECT BLINDED COMPARISON AND ASSESSMENT OF SUBMALAR CHEEK AUGMENTATION BETWEEN RADIESSE PLUS AND VOLUMA | $55,000 | 1 | 2 |
| EVALUATING THE EFFECTS OF CALCIUM HYDROXYLAPATITE (RADIESSE) AND HYALURONIC ACID (VOLUMA) ON HUMAN SKIN ELASTIN STAINING LEVELS AND NASOLABIAL FOLD WRINKLE SCORE STUDY AFTER RADIESSE INJECTION | $41,807 | 0 | 2 |
| A PILOT STUDY EXAMINING THE EFFICIENCY OF PREMIXED CALCIUM HYDROXYLAPATITE FILLER WITH LIDOCAINE TO CORRECT TEMPORAL FOSSAE VOLUME LOSS | $41,200 | 0 | 1 |
| A SINGLE-CENTER, OPEN-LABEL, DOUBLE-BLINDED PILOT STUDY TO COMPARE THE EFFICACY OF ESCALATING DOSES OF INCOBOTULINUMTOXIONA (XEOMIN) FOR EXTENDED TREATMENT OF GLABELLAR RHYTIDS (PREVIOUSLY MERZ IIT-808) | $39,770 | 0 | 3 |
| LONG RUN: LONGitudinal Evaluation and Real-world Evidence of Uniquely Purified incobotulinumtoxinA (Xeomin) in Treatment Naive Participants | $37,304 | 2 | 8 |
| A RETROSPECTIVE ANALYSIS OF FINANCIAL OUTCOME IN >100 PATIENTS SWITCHED FROM BOTOX(ONABOTULINUMTOXINA) TO XEOMIN(INCOBOTULINUMTOXINA) | $34,333 | 0 | 2 |
| A SIDE-BY-SIDE TWO-HAND COMPARISON PILOT STUDY OF CALCIUM HYDROXYLAPATITE WITH AND WITHOUT TRIAMCINALONE ACETATE | $34,250 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Sabrina Fabi, M.d, M.D | Dermatology | San Diego, CA | $1.1M | $0 |
| Dr. Ross Radusky, M.d, M.D | Dermatology | Dallas, TX | $545,422 | $0 |
| Dr. Jeremy Green, M.d, M.D | Dermatology | Coral Gables, FL | $464,136 | $0 |
| Dr. Cheryl Burgess, M.d, M.D | Procedural Dermatology | Washington, DC | $306,934 | $0 |
| Steven Dayan, M.d, M.D | Plastic Surgery | Chicago, IL | $292,496 | $0 |
| Dr. Keith Marcus, Md, MD | Student in an Organized Health Care Education/Training Program | Ann Arbor, MI | $290,930 | $0 |
| Dr. Jennifer Levine, M.d, M.D | Otolaryngology/Facial Plastic Surgery | New York, NY | $223,583 | $0 |
| Dr. David Funt, Md, MD | Specialist | Woodmere, NY | $209,440 | $0 |
| Dr. Brian Biesman, M.d, M.D | Specialist | Nashville, TN | $209,401 | $0 |
| Shino Aguilera, Do, DO | Dermatology | Ft Lauderdale, FL | $207,842 | $0 |
| Dr. Doris Day, Md, MD | Specialist | New York, NY | $200,099 | $0 |
| Alan Durkin, M.d, M.D | Plastic and Reconstructive Surgery | Vero Beach, FL | $195,327 | $0 |
| Dr. Deanne Mraz, Md, MD | Dermatology | Westport, CT | $193,078 | $0 |
| Dr. John Joseph, M.d, M.D | Specialist | Encino, CA | $183,440 | $0 |
| William Werschler, Md, MD | Dermatology | Spokane, WA | $175,958 | $0 |
| Dr. Sheila Barbarino, M.d, M.D | Ophthalmology | Austin, TX | $174,014 | $0 |
| Ava Shamban, Md, MD | Procedural Dermatology | Santa Monica, CA | $170,492 | $0 |
| Kalpna Durairaj, M.d, M.D | Otolaryngology | Sun Valley, CA | $167,585 | $0 |
| Julius Few, Md, MD | Plastic and Reconstructive Surgery | Chicago, IL | $166,916 | $0 |
| Dr. Michael Kane, M.d, M.D | Plastic Surgery | New York, NY | $163,433 | $0 |
| Dr. Jonathan Kaplan, Md, MD | Emergency Medicine | San Francisco, CA | $160,347 | $0 |
| Dr. Jason Bloom, Md, MD | Otolaryngology | Bryn Mawr, PA | $157,104 | $0 |
| Amanda Doyle, M.d, M.D | Dermatology | Brooklyn, NY | $151,422 | $0 |
| Dr. Zbigniew Lorenc, M.d., F.a.c.s, M.D., F.A.C.S | Plastic Surgery | New York, NY | $131,819 | $0 |
| Roberta Del Campo, M.d, M.D | Dermatology | Miami Beach, FL | $129,616 | $0 |
About Merz North America, Inc.
Merz North America, Inc. has made $31.2M in payments to 22,512 healthcare providers, recorded across 119,764 transactions in the CMS Open Payments database. In 2024, the company paid $3.4M. The top product by payment volume is XEOMIN ($5.7M).
Payments were distributed across 267 medical specialties. The top specialty by payment amount is Dermatology ($5.7M to 2,397 doctors).
Payment categories include: Food & Beverage ($7.7M), Consulting ($8.2M), Research ($9.7M), Travel & Lodging ($3.2M).
Merz North America, Inc. is associated with 5 products in the CMS Open Payments database, including Xeomin, XEOMIN, and Asclera.